The global market for pharmacogenomics should grow from $7.7 billion in 2021 to $12.7 billion by 2026 with a compound annual growth rate (CAGR) of 10.6% for the period of 2021-2026.
Report Scope:
This report provides an updated review of pharmacogenomics, including materials, equipment, and strategies, and identifies current and emerging applications for pharmacogenomic products.
The publisher delineates the current market status for pharmacogenomics, defines trends, and presents growth forecasts for the next five years. The pharmacogenomics market is analyzed based on the following segments: technology, product type, end-user, application, and region. In addition, technological issues, including key events and the latest developments, are discussed.
More specifically, the market analysis conducted by the publisher for this report is divided into five sections.
In the first section, an introduction to the topic and a historical review of pharmacogenomic technologies are provided, including an outline of recent events. In this section, current and emerging applications for pharmacogenomics are also identified and grouped in segments (cardiovascular disorders, oncology, respiratory and inflammatory diseases, neurological and psychiatric disorders, health management and predictive medicine, and others).
The second section provides a technological review of pharmacogenomics. This section offers a detailed description of pharmacogenomic materials and equipment, testing methods, and typical strategies used in pharmacogenomics. This section concludes with an analysis of the most important technological developments since 2018, including examples of significant patents recently issued or applied for. The chapter ends with a highlight of the most active research organizations operating in this field and their activities.
The third section entails a global market analysis for pharmacogenomics. Global revenues (sales data in millions of dollars) are presented for each segment (technology, product type, end-user, application, and region), with actual data referring to the years 2019 and 2020, and estimates for 2021. Revenues are at the manufacturing level.
The analysis of current revenues for pharmacogenomics is followed by a detailed presentation of market growth trends, based on industry growth, technological trends, and regional trends. The third section concludes by providing projected revenues for pharmacogenomics within each segment, together with forecast CAGRs for the period 2021 through 2026. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
In the fourth section of the study, which covers the global industry structure, the report offers a list of the leading suppliers of pharmacogenomic products (consumables, instruments, software, and drugs), together with a description of their products. The analysis includes a description of the geographical distribution of these firms and an evaluation of other key industry players. Detailed company profiles of the top players are also provided.
The fifth and final section includes an analysis of recently issued U.S. patents, with a summary of patents related to pharmacogenomic materials, equipment, and applications. Patent analysis is performed by region, country, assignee, patent category, material type, and application.
The Report Includes:
- 60 data tables and 19 additional tables
- An overview of the global market for pharmacogenomics
- Estimation of the market size and analyses of market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation of current market for pharmacogenomics by product category, product type, application, and region and assessment of market growth trends
- Analysis of the pharmacogenomics market, determination of the fastest-growing technologies; and highlights of the current and future market trends and latest technological developments
- Description of the relevant research and development activities along with trends in recently issued U.S. patents
- Identification of current and emerging applications for pharmacogenomics, and details of main pharmacogenomic products and technologies, and main characteristics of these technologies
- Description of commercially available pharmacogenomic products, their production processes and related issues
- Comprehensive profiles of major players in the industry, including Abbott Laboratories, GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Novartis, Oxford Nanopore Technologies (ONT) and Thermo Fisher Scientific (TFS)
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Intended Audience
- Scope of Report
- Methodology and Information Sources
- Market Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Pharmacogenomics
- Global Market for Therapeutic Products
- Milestones in the History of Pharmacogenomics and Recent Events
- Current and Emerging Applications for Pharmacogenomics
- Cardiovascular Disorders
- Oncology
- Respiratory and Inflammatory Diseases
- Neurological and Psychiatric Disorders
- Health Management and Predictive Medicine
- Others
Chapter 4 Technology
- Introduction
- Strategies, Methods, and Materials for Pharmacogenomics
- Single Nucleotide Polymorphisms
- Biomedical Informatics
- Testing Technologies
- Drug Types
- Latest Technological Developments, 2018 to Present
- Machine Learning Algorithm for Pharmacogenomics
- Biological Markers for Cancer Detection
- Pharmacogenomics Screening in Cancer Therapy
- Computational Modeling of Single-Nucleotide Polymorphisms
- Genetic Polymorphisms Associated with Psoriasis
- Method for Preventing Side Effects with Immunotherapy
- Other Relevant R&D Activities
Chapter 5 Global Markets
- Outline of Analysis
- Global Market Summary
- Current Market Status
- Market by Technology
- Market by Product Type
- Market by End User
- Market by Application
- Market by Region
- Market Growth Trends
- Oncology
- Neurological and Psychiatric Disorders
- Respiratory and Inflammatory Diseases
- Cardiovascular Disorders
- Other Applications
- Other Technological Trends
- Regional Trends
- Market Forecast
- Market by Technology
- Market by Product Type
- Market by End User
- Market by Application
- Market by Region
Chapter 6 Global Industry Structure and Company Profiles
- Leading Suppliers of Pharmacogenomic Technologies
- Distribution of Leading Suppliers by Product Type and Region
- Other Industry Players
- Company Profiles
- Abbott Laboratories
- Agilent Technologies
- Bayer
- Becton, Dickinson and Co.
- Bio-Rad Laboratories
- Bristol Myers Squibb
- Diatech Pharmacogenomics
- Glaxosmithkline
- Illumina
- Johnson & Johnson
- Lgc Biosearch Technologies
- Nanostring
- Novartis
- Oxford Nanopore Technologies
- Pacific Biosciences
- Pfizer
- Qiagen
- Roche
- Spartan Bioscience
- Thermo Fisher Scientific
Chapter 7 Patent Analysis
- Introduction
- Summary of Recently Awarded Patents
- General Trends
- Trends by Country and Region
- Trends by Assignee
- Trends by Patent Category
- Trends by Technology Type
- Trends by Application
List of Tables
Summary Table: Global Market for Pharmacogenomics, by Application, Through 2026
Table 1: Global Market for Therapeutic Products, by Region, Through 2026
Table 2: Technological Milestones in Pharmacogenomics
Table 3: Global Patent Applications and Patents Issued on Pharmacogenomics, 1991-2020
Table 4: Number of Cardiovascular Disease Deaths, by Region, 2018
Table 5: Applications of Pharmacogenomics in Cardiovascular Disease, 2021
Table 6: Most Common Types of Cancer and Number of Deaths, 2020
Table 7: Number of Cancer Deaths, by Region, 2020
Table 8: Applications of Pharmacogenomics in Cancer, 2021
Table 9: Applications of Pharmacogenomics in Respiratory and Inflammatory Diseases, 2021
Table 10: Applications of Pharmacogenomics in Neurological Disorders, 2021
Table 11: Applications of Pharmacogenomics in Health Management and Predictive Medicine, 2021
Table 12: Other Applications of Pharmacogenomics, 2021
Table 13: Other Relevant R&D Activities, 2021
Table 14: Drivers, Restraints, Challenges, and Opportunities in the Pharmacogenomics Market
Table 15: Global Market for Pharmacogenomics, by Disease Category, Through 2026
Table 16: Global Market for Pharmacogenomics, by Technology, Through 2021
Table 17: Global Market for Pharmacogenomics, by Product Type, Through 2021
Table 18: Global Market for DNA Sequencing Technologies for Pharmacogenomics, by Product Type, Through 2021
Table 19: Global Market for Polymerase Chain Reaction Technologies for Pharmacogenomics, by Product Type, Through 2021
Table 20: Global Market for Arrays and In Situ Hybridization Technologies for Pharmacogenomics, by Product Type, Through 2021
Table 21: Global Market for Pharmacogenomics, by End User, Through 2021
Table 22: Global Market for Pharmacogenomics, by Application, Through 2021
Table 23: Global Market for Pharmacogenomics, by Region, Through 2021
Table 24: Global Market for Breast Cancer Drugs, by Region, Through 2026
Table 25: Global Market for Lung Cancer Drugs, by Region, Through 2026
Table 26: Global Market for Blood Cancer Drugs, by Region, Through 2026
Table 27: Global Market for Colorectal Cancer Drugs, by Region, Through 2026
Table 28: Global Market for Prostate Cancer Drugs, by Region, Through 2026
Table 29: Global Market for Ovarian Cancer Drugs, by Region, Through 2026
Table 30: Global Market for Pancreatic Cancer Drugs, by Region, Through 2026
Table 31: Global Market for Bladder Cancer Drugs, by Region, Through 2026
Table 32: Global Market for Liver Cancer Drugs, by Region, Through 2026
Table 33: Global Market for General Cancer Drugs, by Region, Through 2026
Table 34: Global Market for Therapies for Alzheimer’s Disease, by Region, Through 2026
Table 35: Global Market for Parkinson’s Disease Drugs, by Region, Through 2026
Table 36: Global Market for Epilepsy Therapeutics, by Region, Through 2026
Table 37: Global Market for ASD Treatment, by Region, Through 2026
Table 38: Global Market for Antidepressant Drugs, by Region, Through 2026
Table 39: Global Market for Drugs for the Respiratory System, by Category, Through 2026
Table 40: Global Market for Drugs for the Respiratory System, by Region, Through 2026
Table 41: Global Market for Arthritis Drugs, by Region, Through 2026
Table 42: Global Market for Cardiovascular Drugs, by Category, Through 2026
Table 43: Global Market for Antihypertensive Drugs, by Type, Through 2026
Table 44: Global Market for Antihyperlipidemic Drugs, by Type, Through 2026
Table 45: Global Market for Blood Modifiers, by Type, Through 2026
Table 46: Global Market for Other Types of Cardiovascular Drugs, by Type, Through 2026
Table 47: Global Market for Cardiovascular Drugs, by Region, Through 2026
Table 48: Global Market for Diabetes Drugs, by Region, Through 2026
Table 49: Global Market for Gastrointestinal Drugs, by Region, Through 2026
Table 50: Global Market for Ophthalmic Drugs, by Region, Through 2026
Table 51: Global Market for Precision Medicine, by Region, Through 2026
Table 52: Global Market for Genomics, by Region, Through 2026
Table 53: Global Market for Drug Repurposing, by Region, Through 2026
Table 54: Global Market for Artificial Intelligence, by Region, Through 2026
Table 55: Global Market for Artificial Intelligence, by Application, Through 2026
Table 56: Global Market for Pharmacogenomics, by Technology, Through 2026
Table 57: Global Market for Pharmacogenomics, by Product Type, Through 2026
Table 58: Global Market for DNA Sequencing Technologies for Pharmacogenomics, by Product Type, Through 2026
Table 59: Global Market for Polymerase Chain Reaction Technologies for Pharmacogenomics, by Product Type, Through 2026
Table 60: Global Market for Arrays and In Situ Hybridization Technologies for Pharmacogenomics, by Product Type, Through 2026
Table 61: Global Market for Pharmacogenomics, by End User, Through 2026
Table 62: Global Market for Pharmacogenomics, by Application, Through 2026
Table 63: Global Market for Pharmacogenomics, by Region, Through 2026
Table 64: Leading Suppliers of Pharmacogenomic Technologies, 2021
Table 65: Leading Suppliers of Equipment, 2021
Table 66: Leading Suppliers of Arrays and In Situ Hybridization Probes, 2021
Table 67: Leading Suppliers of Reagents, Kits and Other Testing Materials, 2021
Table 68: Leading Suppliers of Drugs, 2021
Table 69: Leading Suppliers of Pharmacogenomic Technologies, by Product Type and Region, 2021
Table 70: Other Relevant Industry Players, 2021
Table 71: U.S. Patents Related to Pharmacogenomics, 2021
Table 72: U.S. Patent Trends in Pharmacogenomics, 2017-2021
Table 73: U.S. Patents Related to Pharmacogenomics, by Region, 2021
Table 74: U.S. Patents Related to Pharmacogenomics, by Country, 2021
Table 75: Assignees of U.S. Patents Related to Pharmacogenomics, 2021
Table 76: U.S. Patents Related to Pharmacogenomics, by Patent Category, 2021
Table 77: U.S. Patents Related to Pharmacogenomics, by Technology Type, 2021
Table 78: U.S. Patents Related to Pharmacogenomics, by Application, 2021
List of Figures
Summary Figure: Global Market for Pharmacogenomics, by Application, 2019-2026
Figure 1: Global Market Shares of Therapeutic Products, by Region, 2026
Figure 2: Global Patent Applications and Patents Issued on Pharmacogenomics, 1991-2020
Figure 3: Global Market for Pharmacogenomics, by Disease Category, 2019-2026
Figure 4: Global Market Shares of Pharmacogenomics, by Technology, 2021
Figure 5: Global Market Shares of Pharmacogenomics, by Product Type, 2021
Figure 6: Global Market Shares of DNA Sequencing Technologies for Pharmacogenomics, by Product Type, 2021
Figure 7: Global Market Shares of Polymerase Chain Reaction Technologies for Pharmacogenomics, by Product Type, 2021
Figure 8: Global Market Shares of Arrays and In Situ Hybridization Technologies for Pharmacogenomics, by Product Type, 2021
Figure 9: Global Market Shares of Pharmacogenomics, by End User, 2021
Figure 10: Global Market Shares of Pharmacogenomics, by Application, 2021
Figure 11: Global Market Shares of Pharmacogenomics, by Region, 2021
Figure 12: Global Market Shares of Breast Cancer Drugs, by Region, 2026
Figure 13: Global Market Shares of Lung Cancer Drugs, by Region, 2026
Figure 14: Global Market Shares of Blood Cancer Drugs, by Region, 2026
Figure 15: Global Market Shares of Colorectal Cancer Drugs, by Region, 2026
Figure 16: Global Market Shares of Prostate Cancer Drugs, by Region, 2026
Figure 17: Global Market Shares of Ovarian Cancer Drugs, by Region, 2026
Figure 18: Global Market Shares of Pancreatic Cancer Drugs, by Region, 2025
Figure 19: Global Market Shares of Bladder Cancer Drugs, by Region, 2026
Figure 20: Global Market Shares of Liver Cancer Drugs, by Region, 2026
Figure 21: Global Market Shares of Cancer Drugs, by Region, 2026
Figure 22: Global Market Shares of Therapies for Alzheimer’s Disease, by Region, 2026
Figure 23: Global Market Shares of Parkinson’s Disease Drugs, by Region, 2026
Figure 24: Global Market Shares of Epilepsy Therapeutics, by Region, 2026
Figure 25: Global Market Shares of ASD Treatment, by Region, 2026
Figure 26: Global Market Shares of Antidepressant Drugs, by Region, 2026
Figure 27: Global Market Shares of Drugs for the Respiratory System, by Category, 2026
Figure 28: Global Market Shares of Drugs for the Respiratory System, by Region, 2026
Figure 29: Global Market Shares of Arthritis Drugs, by Region, 2026
Figure 30: Global Market Shares of Cardiovascular Drugs, by Category, 2026
Figure 31: Global Market Shares of Antihypertensive Drugs, by Type, 2026
Figure 32: Global Market Shares of Antihyperlipidemic Drugs, by Type, 2026
Figure 33: Global Market Shares of Blood Modifiers, by Type, 2026
Figure 34: Global Market Shares of Other Types of Cardiovascular Drugs, by Type, 2026
Figure 35: Global Market Shares of Cardiovascular Drugs, by Region, 2026
Figure 36: Global Market Shares of Diabetes Drugs, by Region, 2026
Figure 37: Global Market Shares of Gastrointestinal Drugs, by Region, 2026
Figure 38: Global Market Shares of Ophthalmic Drugs, by Region, 2026
Figure 39: Global Market Shares of Precision Medicine, by Region, 2026
Figure 40: Global Market Shares of Genomics, by Region, 2026
Figure 41: Global Market Shares of Drug Repurposing, by Region, 2026
Figure 42: Global Market Shares of Artificial Intelligence, by Region, 2026
Figure 43: Global Market Shares of Artificial Intelligence, by Application, 2026
Figure 44: Global Market Shares of Pharmacogenomics, by Technology, 2026
Figure 45: Global Market Shares of Pharmacogenomics, by Product Type, 2026
Figure 46: Global Market Shares of DNA Sequencing Technologies for Pharmacogenomics, by Product Type, 2026
Figure 47: Global Market Shares of Polymerase Chain Reaction for Pharmacogenomics, by Product Type, 2026
Figure 48: Global Market Shares of Arrays and In Situ Hybridization Technologies for Pharmacogenomics, by Product Type, 2026
Figure 49: Global Market Shares of Pharmacogenomics, by End User, 2026
Figure 50: Global Market Shares of Pharmacogenomics, by Application, 2026
Figure 51: Global Market Shares of Pharmacogenomics, by Region, 2026
Figure 52: Distribution of Suppliers of Pharmacogenomic Technologies, by Product Type and Region, 2021
Figure 53: U.S. Patent Trends in Pharmacogenomics, 2017-2021
Figure 54: U.S. Patent Shares of Pharmacogenomics, by Region, 2021
Figure 55: U.S. Patent Shares of Pharmacogenomics, by Country, 2021
Figure 56: U.S. Patent Shares of Pharmacogenomics, by Patent Category, 2021
Figure 57: U.S. Patent Shares of Pharmacogenomics, by Material Type, 2021
Figure 58: U.S. Patent Shares of Pharmacogenomics, by Application, 2021
Executive Summary
Pharmacogenomics is a group of technologies focusing on the application of genomic testing to determine drug response. This relatively new field of life sciences, which combines biology, pharmacology and medicine to develop new drugs and optimize their dosage, is bringing numerous advantages in healthcare, including personalized medicine, therapies with high specificity, remedies for rare and hard-to-cure diseases, and treatments with reduced side effects.
The publisher has identified five main sectors in which pharmacogenomics finds current and potential applications: cardiovascular disease; neurological and psychiatric disorders; oncology; respiratory and inflammatory diseases; and health management and predictive medicine.
This study provides an updated review of pharmacogenomic technologies, including materials, equipment, strategies, and applications. It also offers a detailed market analysis for pharmacogenomics by segment (technology, product type, end-user, application, and region), describing technical aspects and trends that will affect future growth of this market.
Applications for oncology currently account for the largest share of the market. Within this segment, pharmacogenomic products are being used primarily for the treatment of breast, lung and blood cancer.
Companies Mentioned
- Abbott Laboratories
- Agilent Technologies
- Bayer
- Becton, Dickinson and Co.
- Bio-Rad Laboratories
- Bristol Myers Squibb
- Diatech Pharmacogenomics
- Glaxosmithkline
- Illumina
- Johnson & Johnson
- Lgc Biosearch Technologies
- Nanostring
- Novartis
- Oxford Nanopore Technologies
- Pacific Biosciences
- Pfizer
- Qiagen
- Roche
- Spartan Bioscience
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | April 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 7.7 Billion |
| Forecasted Market Value ( USD | $ 12.7 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
